MarketPulse

endometrial cancer

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's AP3 Platform Shows Promise: ACR-368 Synergies Highlighted at AACR 2026

Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.
ACRVendometrial cancerAACR Annual Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC